Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 29, 2003
Business Overview: The Company is the largest distributor of healthcare products and services to office-based practitioners in North America and Europe. Operations are divided into two segments: Healthcare Distribution (dental, medical, and international) and Technology (practice management software).
Key Financial Metrics
| Metric (in thousands) | Q1 2003 | Q1 2002 |
|---|---|---|
| Net Sales | $737,997 | $647,093 |
| Gross Profit | $201,417 | $178,390 |
| Gross Margin | 27.3% | 27.6% |
| Operating Income | $42,205 | $35,198 |
| Net Income | $24,766 | $19,730 |
| Diluted EPS | $0.55 | $0.45 |
| Cash and Equivalents | $186,995 | $93,421 |
| Long-Term Debt | $242,868 | $242,561 |
| Operating Cash Flow | $(14,085) | $(38,786) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 14.0% ($90.9 million) year-over-year. The Healthcare Distribution segment drove 97% of this growth, with significant increases in Medical (19.8%) and International (22.5%) segments. The Technology segment grew 18.9%.
- Profitability: Operating income rose 20% to $42.2 million. Net income increased 25.5% to $24.8 million. Diluted EPS improved from $0.45 to $0.55.
- Margins: Overall gross margin decreased slightly by 0.3% to 27.3%, primarily due to sales mix changes in the medical business. However, Technology segment margins improved by 2.0% to 77.1% due to the "MarketOne" direct-to-customer initiative.
- Cash Flow: Operating cash flow usage improved significantly, decreasing from a $38.8 million outflow in Q1 2002 to a $14.1 million outflow in Q1 2003. This was driven by a net increase in working capital usage (paying down accounts payable from year-end inventory buy-ins) offset by higher net income.
- Capital Allocation: The Company repurchased 152,500 shares of common stock for $6.5 million during the quarter.
Guidance, Outlook, and Risks
- Capital Expenditures: Management expects to invest more than $35.0 million in 2003 for facility modernization, computer infrastructure, and operational integration.
- Seasonality: The business is seasonal, with Q1 typically showing lower sales and profits compared to Q4 due to prior quarter purchasing patterns.
- Legal Proceedings:
- Latex Glove Litigation: The Company is a defendant in approximately 55 product liability cases, 45 of which involve allergic reactions to latex gloves. Manufacturers have withheld indemnification pending product identification.
- Software Class Action: A class action suit regarding practice management software (Stromboe v. Henry Schein) was decertified by the Texas Supreme Court in October 2002. A motion for rehearing was denied in May 2003, but the case remains in trial court.
- Vaccine Dispute: A nationwide class action regarding vaccine sales is pending in New Jersey; damages are unspecified.
- Risk Factors: Key risks include intense competition, consolidation in the healthcare industry, regulatory changes, product liability claims, and foreign currency fluctuations affecting international operations.
Investor Verification Checklist
- Working Capital Trends: Verify the sustainability of the $41 million decrease in accounts payable and accruals, which contributed to negative operating cash flow.
- Legal Exposure: Monitor the status of the latex glove litigation and the potential for indemnification claims against manufacturers.
- Segment Mix: Assess the impact of the declining gross margin in the Healthcare Distribution segment versus the high-margin growth in the Technology segment.
- Debt Obligations: Review the maturity schedule for the $130 million Senior Notes (due 2009) and $100 million Senior Notes (principal payments starting 2006).
- Stock Repurchases: Confirm the remaining authorization under the $2 million share repurchase program announced in March 2003.